Furthermore, a multicenter study showed that serum extracellular-vesicle-derived LINC00853 discriminated all-stage HCC from non-HCC liver disease with an AUC of 0.93 (95% CI, 0.887–0.966) and outperformed AFP in early (mUICC stage I) tumors, achieving 94% sensitivity and 90% specificity versus 9% and 73% for AFP; notably, LINC00853 remained positive in 97% of AFP-negative early HCC cases [19]. Here, AFP is linked to hepatocellular carcinoma.